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Introduction: Hypertension, a risk factor for cardiovascular disease (CVD), is frequently associated with other CVD
risk factors. Despite recent improvement in blood pressure (BP) control in Europe, a substantial proportion of
patients fail to achieve BP targets.
Methods: This retrospective cohort study used longitudinal patient databases (LPDs) in France and Italy to examine
CVD risk profiles, treatment patterns, and BP goal attainment in hypertensive patients treated in real-world clinical
practice between 2007 and 2008. Overall, 147,964 and 140,189 eligible patients from LPDs in France and Italy,
respectively, were prescribed an antihypertensive medication in 2007.
Results: Among patients with hypertension with other risk factors (France 88 %, Italy 83 %), the most prevalent risk
factors were being elderly (France 66.9 %, Italy 70. 9 %), followed by hypertension combined with dyslipidemia
(France 36.7 %, Italy 23.9 %) and isolated systolic hypertension (France 32.5 %, Italy 24.2 %). The odds ratios for
target BP attainment were significantly (p < 0.001) higher in patients with hypertension without other risk factors vs
patients with hypertension with other risk factors (1.41 [95 % confidence interval 1.35, 1.48] in France; 1.38 [1.31,
1.46] in Italy). The odds of BP control were significantly lower for patients with vs patients without an associated
CVD risk factor (range 0.54 to 1.10 France; 0.59 to 1.17 Italy).
Discussion: This study demonstrates that the majority of treated hypertensive patients in France and Italy have at
least one additional CVD risk factor. Despite treatment with antihypertensive medications, blood pressure
attainment was substantially less optimal in patients with an associated CVD risk factor compared to patients
without an associated CVD risk factor.
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The majority of hypertensive patients have concomitant
cardiovascular disease (CVD) risk factors [1, 2], and
CVD risk is higher among these hypertensive patients
compared with the general population. Response to anti-
hypertensive therapy may differ between those at high
and low risk [3, 4]. For example, achieving blood pres-
sure target may be more difficult for patients with con-
comitant cardiovascular risk factors or advanced age
while needing more frequent therapy changes or dose* Correspondence: wei.wu@merck.com
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creativecommons.org/publicdomain/zero/1.0/adjustments [5]. Consequently, hypertension treatment
guidelines have been oriented towards individual man-
agement, taking into account all concomitant risk factors
rather than focusing only on blood pressure measures
for determining the need and type of treatment [6]. Both
the 2007 and 2013 European guidelines have indicated
that diagnosis and management of hypertension should be
informed by the quantification of total CVD risk and
interpreted using a physician’s knowledge and experience
[7, 8]. In addition to lifestyle changes, the 2013 evidence-
based guidelines recommend therapeutic approaches for
all patients, including the elderly and patients with dia-
betes, cardiovascular disease, cerebrovascular disease, or
renal disease to achieve a blood pressure target of <140/e distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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mend a lower blood pressure target of 130/80 mmHg for
patients with diabetes; patients with cerebrovascular,
heart, or renal disease; obese patients, and those with mul-
tiple risk factors [7].
Despite overall improvement in blood pressure treat-
ment and control over the past decades in Europe and
the USA [9, 10], a substantial proportion of patients are
still not achieving their blood pressure goals [3, 11, 12].
A cross-sectional study conducted in 12 European coun-
tries showed that only 38.8 % of hypertensive patients
achieved the blood pressure target of 140/90 mmHg in
real-life clinical practice [11]. Belletti et al. showed that
compared to patients with hypertension and no ad-
ditional cardiovascular risk factors, adjusted odds ratios
for attainment of target blood pressure were significantly
lower in patients with associated risk factors [5]. Wong
et al. showed that although treatment rates were lowest
in lower risk individuals and highest in patients with car-
diovascular disease, blood pressure (BP) control rates
were best in lower risk patients and worst in the higher
risk patients [4]. This indicates that the level of unmet
medical need and suboptimal care may differ across
patient populations.
To help better understand the remaining unmet needs
in blood pressure treatment, we examined CVD risk
profiles, treatment patterns, and blood pressure goal at-
tainment in hypertensive patients treated in actual clin-
ical practices in France and Italy. The specific study
objectives were (1) to identify demographic characteris-
tics and CVD risk profiles of adult hypertensive patients,
(2) to examine and document antihypertension treat-
ment patterns in segments of patient populations with
and without hypertension with other risk factors, and (3)




This was a retrospective, observational, longitudinal,
single-cohort database study conducted in primary
health care practices in France and Italy. The study
period was 1 January 2005 to 31 December 2008.
Data source
Primary care data were extracted from Cegedim Stra-
tegic Data’s (CSD’s) proprietary, longitudinal patient da-
tabases (LPDs) in Italy and France. CSD’s LPDs hold
anonymized electronic patient records collected from
700 participating general practices (GPs) in Italy who
use the Millewin patient management software. CSD’s
LPD in France holds similar data from 1200 participat-
ing GPs who use the Doc’Ware patient management
software. The panels of volunteering participants areselected to be nationally representative according to geo-
graphical area, age, and gender. CSD’s LPDs contain
patient-level prescriptions, diagnoses, demographics, and
other medical data entered at the time of consultation
by participating GPs and include routinely collected
electronic health records for more than 800,000 patients
in Italy and 1,600,000 patients in France. Information on
diagnoses is encoded at the time of information collec-
tion, the codes being mapped on the tenth revision of
the International Classification of Disease (ICD-10). Pre-
scription data contain the dispensed drug name, the
Anatomical Therapeutic Chemical (ATC) classification
category, dose regimen, and prescription duration.
Study population
The study population was defined as those aged 18 years
or older at index date who fulfilled the following criteria
during the index period (1 January 2007 to 31 December
2007, see Additional file 1: Figure S1): having a diagnosis
of primary hypertension (ICD-10: I10) and at least one
prescription for an antihypertensive medication (ATC
codes C02, C03, C07, C08, and C09). In addition, pa-
tients had to have a minimum of 2 years of recorded ac-
tivity in the database prior to the index date (baseline
period, see Additional file 1: Figure S1) and at least
12 months of recorded activity in the database post
index date and prior to study end on 31 December 2008
(follow-up period, see Additional file 1: Figure S1) to en-
sure that patients were longitudinally followed, including
sufficient history and follow-up to meet our study ob-
jective. The index date, which was the date of inclusion
for each patient, was determined to be the date of first
observed prescription for any antihypertensive drug dur-
ing the index period (Additional file 1: Figure S1). Pa-
tients were excluded if they had a diagnosis of secondary
hypertension (ICD-10: I15) in the 2 years prior to the
index date.
Data collection and organization
Patient-level demographic characteristics and clinical data
extracted from the databases at index date as baseline
measures were as follows: demographics and vital signs
(blood pressure and last laboratory result prior to the
index date for lipids, glycosylated hemoglobin (HbA1c),
and serum creatinine). Index medication was defined as
the last prescription of antihypertensive medication(s)
prior to or on the index date. Medical history data were
extracted during the baseline period according to ICD-10
classification. These data were used to stratify the study
population into non-mutually exclusive patient groups
based on specific CVD risk profiles (definitions given in
Additional file 2: Table S1) [7].
The last measure of blood pressure prior to the end of
the follow-up period was collected. Treatment data
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and duration) were also collected during the follow-up
period and were stratified into monotherapies, fixed-
dose combination medications, and free-dose combin-
ation therapies. The following medications were defined
as categories of monotherapy: centrally acting agents, di-
uretics, beta blockers, calcium-channel blockers (CCBs),
angiotensin-converting enzyme inhibitors (ACEIs), or
angiotensin II receptor blockers (ARBs). Fixed-dose
combination medications were defined as diuretic + beta
blocker, beta blocker + CCB, ACEI + diuretic, ACEI +
CCB, ARB + diuretic, or ARB + CCB. Free-dose combi-
nations were those combination therapies that were not
fixed-dose.
The study population was stratified into two treatment
groups: treatment-naive and previously treated. The
treatment-naive patient group had no antihypertensive
medication prescribed during the baseline period, and
the index prescription was regarded as the first-line ther-
apy. Those in the previously treated group were pre-
scribed at least one antihypertensive medication during
the baseline period.
Data analysis
Descriptive statistics were employed using SAS 9.2 soft-
ware to assess patient characteristics, clinical profile,
treatment pattern, and blood pressure control. No sam-
ple size calculation was necessary; data collection was
exhaustive given the defined criteria. Categorical data
were summarized by sample size and/or percentage
(compared to the size of completed data). Mean, median,
standard deviation, and range were reported for continu-
ous variables. Univariate binary logistic regressions were
performed to predict the achievement of blood pressure
goal with selected predictors or covariates in the survey.
Estimated odds ratios (OR) were presented with 95 %
confidence intervals in order to assess the relationship
between the achievement of blood pressure goal and the
presence of the factor, one by one. Next, 11 predictor
variables were selected for France and 8 predictor vari-
ables for Italy in the multivariate model when p values
were less than 0.05. A stepwise multivariate logistic re-
gression was performed to keep only the variables sig-
nificant at the 0.05 level, and adjusted ORs with 95 % CI
were then calculated.
The last blood pressure measurement within the
follow-up period was used to identify the blood pressure
control rates based on levels defined in the 2007 ESH/
ESC treatment guidelines in each defined patient seg-
ment [7]. The 2007 guidelines were utilized since the
index dates for the study population were 1 January
2007 to 31 December 2007. The index antihypertensive
medication prescription for each patient was compared
with subsequent prescription(s) to assess treatmentpatterns—switches, add-ons, and discontinuation—in
both treatment groups. Switch was defined as the re-
placement of the index medication with another antihy-
pertensive medication; only the first observed switch was
considered to capture the initial switch decision. Add-on
was defined as the addition of any antihypertensive
medication to the index medication during the follow-
up period (a repeat prescription for the index medication
in addition to prescription of another drug on a unique
script). Discontinuation was defined as terminating ther-
apy with the index medication and not receiving another
prescription for a period of at least twice the expected
duration of the previous prescription (assumed days of
medication supplied).Results
Prevalence of HTN with other risk factors by
subpopulation and baseline characteristic
A total of 147,964 and 140,189 patients from LPDs in
France and Italy, respectively, were prescribed an antihy-
pertensive medication during the index period and were
eligible for the study. Baseline patient demographics and
clinical characteristics are reported in Additional file 3:
Table S2. Gender, age, BMI, SBP, and DBP distributions
were similar among patients in both countries. The
mean age of patients was 66 years in France and 68 years
in Italy, with slightly more patients being women in both
countries (France 52.2 %, Italy 56.6 %). The majority of
patients were defined as having hypertension with other
risk factors (France 88 %, Italy 83 %). Among them, eld-
erly patients with hypertension were the largest preva-
lent patient segment in each country (France 66.9 %,
Italy 70.9 %), followed by patients with hypertension and
dyslipidemia (France 36.7 %, Italy 23.9 %) and patients
with isolated systolic hypertension (France 32.5 %, Italy
24.2 %).Antihypertensive treatment patterns
Index medication patterns in naive and treatment-
experienced patients
In France, angiotensin II receptor blockers (ARBs,
32.8 %) were the medication group most commonly
prescribed at index date among treatment-naive pa-
tients (see Table 1). Calcium-channel blockers (CCBs,
12.9 %), beta blockers (12.7 %), angiotensin-converting
enzyme inhibitors (ACEIs, 10.3 %), and diuretics (9.4 %)
were the next most commonly prescribed groups of medi-
cation among these patients. Among previously treated
patients, treatment combinations not classified in the
fixed-dose combinations were the most prescribed group
(41.6 %), followed by ARBs alone (13.0 %), fixed-dose
combinations of ARB + diuretic (10.5 %), beta blockers
alone (8.9 %), and calcium-channel blockers alone (6.0 %).
Table 1 Prescription pattern at index date










patients (n = 131,162)
Total (n = 140,189)
ACEI 988 (10.3 %) 7651 (5.5 %) 8639 (5.8 %) 3438 (38.1 %) 25,593 (19.5 %) 29,031 (20.7 %)
ARB 3132 (32.8 %) 17,937 (13.0 %) 21,069 (14.2 %) 1242 (13.8 %) 13,663 (10.4 %) 14,905 (10.6 %)
Beta blockers 1210 (12.7 %) 12,308 (8.9 %) 13,518 (9.1 %) 1283 (14.2 %) 13,444 (10.2 %) 14,727 (10.5 %)
Centrally acting agents 312 (3.3 %) 1673 (1.2 %) 1985 (1.3 %) 40 (0.4 %) 633 (0.5 %) 673 (0.5 %)
CCB 1238 (12.9 %) 8241 (6.0 %) 9479 (6.4 %) 901 (10.0 %) 15,681 (12.0 %) 16,582 (11.8 %)
Diuretics 902 (9.4 %) 7131 (5.2 %) 8033 (5.4 %) 89 (1.0 %) 312 (0.2 %) 401 (0.3 %)
ACEI + diuretica 291 (3.0 %) 5614 (4.1 %) 5905 (4.0 %) 1026 (11.4 %) 18,420 (14.0 %) 19,446 (13.9 %)
ARB + CCBa 17 (0.2 %) 13 (0.0 %) 30 (0.0 %) – – –
ARB + diuretica 428 (4.5 %) 14,487 (10.5 %) 14,915 (10.1 %) 539 (6.0 %) 14,079 (10.7 %) 14,618 (10.4 %)
Beta blocker + CCBa 10 (0.1 %) 1037 (0.7 %) 1047 (0.7 %) 0 (0.0 %) 3 (0.0 %) 3 (0.0 %)
Beta blocker + diuretica 231 (2.4 %) 3920 (2.8 %) 4151 (2.8 %) 39 (0.4 %) 96 (0.1 %) 135 (0.1 %)
CCB + ACEIa 45 (0.5 %) 766 (0.6 %) 811 (0.5 %) – – –
Free-dose combinationsa 759 (7.9 %) 57,623 (41.6 %) 58,382 (39.5 %) 430 (4.8 %) 29,238 (22.3 %) 29,668 (21.2 %)
ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin II receptor blockers, CCB calcium-channel blockers
aFixed-dose combinations
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scribed index medication group among treatment-naive
patients, followed by beta blockers alone (14.2 %), ARBs
alone (13.8 %), fixed-dose combinations of ACEI + diur-
etic (11.4 %), calcium-channel blockers alone (10.0 %),
and fixed-dose combinations of ARB + diuretic (6.0 %).
Among previously treated patients, treatment combinations
not classified in the fixed-dose combinations were the most
prescribed group at index date (22.3 %), followed by ACEIs
alone (19.5 %), fixed-dose combinations of ACEI + diur-
etic (14.0 %), calcium-channel blockers alone (12.0 %),
fixed-dose combinations of ARB + diuretic (10.7 %),
ARBs (10.4 %), and beta blockers alone (10.2 %).Medication changes during follow-up period in naive and
treatment-experienced patients
With the exception of patients treated with fixed-dose
combinations of ARB + CCB, treatment discontinuations
were more frequent among treatment-naive French pa-
tients than among previously treated patients in all treat-
ment groups. The difference ranged from 26.1 % for
treated with fixed combinations of ACEI + diuretic to
42.8 % for patients treated with fixed-dose combinations
of CCB + ACE at index date (Fig. 1a, b). Depending on
the type of treatment prescribed at index date, treatment
switches occurred between 20.0 % (beta blocker + CCB)
and 53.3 % (CCB + ACEI) of treatment-naive patients
and between 14.8 % (ARB + diuretic) and 46.2 % (ARB +
CCB) of previously treated patients. Add-ons of a new
class were prescribed in no more than 1.1 % of naivepatients for all treatment groups and no more than
1.7 % of previously treated patients.
Among Italian patients, drug discontinuations ranged
from 14.8 % for the ARB alone subgroup to 36 % for the
diuretics alone subgroup in treatment-naive patients.
Discontinuation rate varied from 10.2 to 33.3 % across
index medication subgroups in previously treated pa-
tients. Treatment switches were generally less frequent
than discontinuation in both treatment-naive patients
(from 2.5 to 14.6 % across index medication subgroups)
and previously treated patients (from 0 to 21.5 %).
Target blood pressure attainment after 12 months
follow-up
Target blood pressure attainment rate across subpopulations
Attainment of target blood pressure after 12 months
was determined for patients with a blood pressure
value available in the LPDs during the follow-up
period. The proportion of patients with these data
available was 76.7 % for French patients and 39.1 %
for Italian patients. The proportion of patients attain-
ing target blood pressure after 12 months of follow-up
was greatest in the segment of patients with hyperten-
sion without other risk factors and reached 78.4 % and
71.2 % of French and Italian patients, respectively
(Fig. 2). In patients with hypertension with other risk
factors, the overall proportion of target blood pressure
attainment was 72.6 % in France and 65.1 % in Italy.
These proportions ranged from 64.7 % to 74.5 % for
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Fig. 1 Changes in treatment for naive and for previously treated patients by treatment subgroup. a Treatment patterns in naive patients included
in the French longitudinal patient database. b Treatment patterns in previously treated patients included in the French longitudinal patient
database. c Treatment patterns in naive patients included in the Italian longitudinal patient database. d Treatment patterns in previously treated
patients included in the French longitudinal patient database
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Based on the univariate logistic regression analysis, the
odds ratios for target BP attainment were significantly
(p < 0.001) higher in patients with hypertension without
other risk factors vs patients with hypertension with
other risk factors (1.41 [95 % confidence interval (CI)
1.35, 1.48] in France; 1.38 [1.31, 1.46] in Italy). The odds
of BP control were significantly lower for patients with
vs patients without an associated CVD risk factor (range
0.54 to 1.10 in France and 0.59 to 1.17 in Italy).
In France, multiple stepwise logistic regression (Table 2)
showed that factors associated with lower odds of attaining
blood pressure goal included being male >65 years (OR =
0.87; 95 % CI 0.84, 0.90), being female >65 years (OR =
0.82; 95 % CI 0.79, 0.85), isolated hypertension (OR = 0.76;
95 % CI 0.74, 0.79), having obesity (OR = 0.92; 95 % CI
0.89, 0.95) or diabetes (OR = 0.93; 95 % CI 0.90, 0.97) co-
morbid with hypertension, and higher baseline diastolic
(OR = 0.99; 95 % CI 0.99, 0.99) and systolic blood pressure
(OR = 0.96; 95 % CI 0.96, 0.96). Conversely, patients having
CVD comorbid with hypertension (OR = 1.09; 95 % CI
1.01, 1.17), heart disease comorbid with hypertension (OR= 1.06; 95 % CI 1.02, 1.11), and peripheral vascular disease
comorbid with hypertension (OR = 1.13; 95 % CI 1.05, 1.21)
and drug-naive patients (OR = 1.76; 95 % CI 1.65, 1.87) had
higher odds of reaching blood pressure goals in France. In
Italy, factors significantly associated with lower odds of
attaining blood pressure goal included being female
>65 years (OR = 0.90; 95 % CI 0.86, 0.94), hypertension
combined with obesity (OR = 0.86; 95 % CI 0.81, 0.90), iso-
lated systolic hypertension (OR = 0.80; 95 % CI 0.76, 0.84),
and higher baseline diastolic (OR = 0.99; 95 % CI 0.99, 1.00)
and systolic blood pressure (OR = 0.96; 95 % CI 0.96, 0.97),
whereas having comorbid heart disease with hypertension
(OR = 1.17; 95 % CI 1.09, 1.25), having hypertension with-
out other risk factors (OR = 1.08; 95 % CI 1.01, 1.17), or
being drug naive (OR = 1.91; 95 % CI 1.75, 2.08) increased
the odds of achieving blood pressure target (Table 2).
Discussion
The results of this analysis showed that, consistent with
previous findings in the general population, more than
four out five patients in France and Italy with hyperten-
sion who are already treated by general practitioners had
B. Italy LPD
A. France LPD
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Fig. 2 Blood pressure goal attainment across patient segments after 12 months of follow-up (missing data not included in analyses). a Goal
attainment in patients included in the French longitudinal patient database. Forest plot was derived from univariate regression analysis and
shows odds ratios and 95 % confidence intervals for attainment of BP target (140/90 mm Hg). b Goal attainment in patients included in the
Italian longitudinal database. Forest plot was derived from univariate regression analysis and shows odds ratios and 95 % confidence intervals
for attainment of BP target (140/90 mm Hg)
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in this population, attainment of target blood pressure
after 1 year of treatment was better in those with hy-
pertension without other risk factors than in patients
with hypertension with other risk factors [3, 5, 13]. In
addition, this analysis identified that most treatment-
naive patients in France and Italy were prescribed a sin-
gle class of drug, and previously treated patients in both
countries were being managed with combinations of
drugs not considered fixed-dose combinations.
As noted in the 2013 guidelines and in other reports
from industrialized countries, only a small proportion
of patients with hypertension suffers from elevated BP
alone [8]. In the current analysis, older age was by farthe most prevalent associated risk factor, followed by
dyslipidemia and isolated systolic hypertension. Our
findings are consistent with other reports in which the
prevalence of patients with hypertension associated
with at least one risk factor ranged between ~74 % and
95 % in industrialized countries. In those studies, add-
itional risk factors of patients with hypertension were
similar to those in the present analysis including age
≥65 years and a high prevalence of obesity and dyslipid-
emia, especially in women [3, 5, 13]. The addition of one
or more cardiovascular risk factors to BP may lead to a
total CV risk profile that is greater than the sum of its
individual elements. That said, among treated hyperten-
sive patients, there are certain subgroups of hypertensive
Table 2 Factors associated with blood pressure goal attainment
based on multivariate stepwise logistic regression model
(N = 107,353)
n OR 95 % CI p value
France
Female >65 years 31,777 0.82 0.79, 0.85 <0.001
Male >55 years 40,627 0.87 0.84, 0.90 <0.001
HTN + obesity 25,141 0.92 0.89, 0.95 <0.001
HTN + diabetes 18,316 0.93 0.90, 0.97 <0.001
Isolated systolic HTN 40,656 0.76 0.74, 0.79 <0.001
HTN + CVD 4104 1.09 1.01, 1.17 <0.033
HTN + heart disease 14,944 1.06 1.02, 1.11 <0.006
HRN + PVD 4534 1.13 1.05, 1.21 <0.001
Drug naive 6251 1.76 1.65, 1.87 <0.001
BL diastolic BP 107,353 0.99 0.99, 0.99 <0.001
BL systolic BP 107,353 0.96 0.96, 0.96 <0.001
Italy
Female >65 years 18,080 0.9 0.86, 0.94 <0.001
HTN + obesity 7365 0.86 0.81, 0.90 <0.001
Isolated systolic HTN 15,977 0.8 0.76, 0.84 <0.001
HTN + heart disease 4813 1.17 1.09, 1.25 <0.001
Uncomplicated HTN 5682 1.08 1.01, 1.17 <0.033
Drug naive 3134 1.91 1.75, 2.08 <0.001
BL diastolic BP 45,060 0.99 0.99, 1.00 <0.001
BL systolic BP 45,060 0.96 0.96, 0.97 <0.001
BL baseline, BP blood pressure, CI confidence interval, CVD cardiovascular
disease, HTN hypertension, OR odds ratio, PVD peripheral vascular disease
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controlled.
In this study, the results showed that attainment of
target blood pressure after 1 year of treatment was better
in those with hypertension without other risk factors
than in the patient segments with hypertension with
other risk factors. These results substantiate those of the
PRATIK study and the Wong et al. study, which showed
that patients at high CVD risk were less likely to be con-
trolled for hypertension than patients at lower CVD risk
[4, 14]. In the current analysis, despite the many differ-
ent treatment options available, the majority of patients
in hypertension segments with additional risk factors did
not achieve target blood pressure. These findings are
also consistent with previous results showing poor at-
tainment of target blood pressure using similar assess-
ment criteria. Estimates suggest that 53.5 % of those
with hypertension in the USA had inadequately con-
trolled blood pressure [15]. Studies in Italy and Europe
indicate that more than 60 % of hypertension patients
treated with antihypertensive medications failed to reach
blood pressure control [11, 12]. In the PRATIK and
Wong studies, higher risk individuals were more likelyto be treated with monotherapy than with combination
therapies, which may account for the lower likelihood of
attainment of BP target [4, 14].
Current guidelines state that diuretics, beta blockers,
calcium antagonists, ACEIs, and ARBs are all appropri-
ate medications for the initiation and maintenance of
antihypertensive treatment, either as monotherapy or in
some combinations [8]. More than one third of all
treatment-naive patients were prescribed ARBs (France
32.8 %) and ACEIs (Italy 38.4 %). This may be related to
a large proportion of patients with associated metabolic
disorders and the possible contraindication of diuretics
in patients with metabolic syndrome [16]. Physician pre-
scription patterns differed for treatment-naive patients
and previously treated patients in the two countries.
Among treatment-naive patients in France, most pa-
tients were prescribed a single class of drug, mainly
ARBs, followed by CCBs, beta blockers, ACEIs, and
diuretics. Previously treated patients were mostly pre-
scribed free combinations, a choice that might be a conse-
quence of a previously inadequate patient response when
using monotherapy or fixed-dose combinations on difficult-
to-manage subpopulations of patients. In addition, the
current findings can be paralleled with the lower proportion
of previously treated patients who were prescribed treat-
ment combinations in Italy. A relatively low proportion
of index medication changes and discontinuations
were observed among the previously treated patients
compared with the treatment-naive patients in France.
This might be a consequence of historic (prior to
index date) therapeutic changes which made the previ-
ously treated subpopulation generally more stable with
regard to their treatments during the follow-up period.
Treatment-naive patients in Italy generally had more
index medication discontinuations but less treatment
changes than previously treated patients. Given that
the majority of study patients with hypertension with
other risk factors do not reach their blood pressure
goal and that there is relatively little switching, it
would appear that physicians were not fully utilizing
recommended blood pressure targets to inform deci-
sions about necessary changes in antihypertensive
medication. Further assessment of this patient popula-
tion with regard to identifying factors independently
associated with achieving blood pressure goal might
be an appropriate next step and could be used to bet-
ter inform physicians in general clinical practice.
Factors such as age, compliance, number of concomi-
tant medications, and disease severity, among others, all
play a role in creating individual disease states. The ob-
servation that patients with cardiovascular conditions
comorbid with hypertension had higher odds of attain-
ing blood pressure target was somewhat unexpected.
One can speculate that these patients had modified their
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being treated for their comorbid conditions, resulting in
more frequent doctor visits, more aggressive treatment,
and potentially better follow-up. Factors associated with
lower odds of attaining blood pressure goals included in-
creased age in males and females, and isolated systolic
hypertension. Since isolated hypertension accounts for
87 % of cases in older adults, these results were not sur-
prising [17]. Patients with other conditions, such as
older age, diabetes, and obesity, may not be perceived as
having a need for aggressive treatment, leading to clin-
ical inertia. More aggressive and/or more targeted treat-
ment options may be needed for these patients in order
for them to achieve their target blood pressure.
Importantly, there may be multiple challenges present
in treating patients with certain comorbidities along with
hypertension. For example, despite the availability of
several antihypertensive medications (including fixed-
dose combinations intended to simplify dosing, reduce
costs, and improve compliance [18]), prescribing mul-
tiple medications to treat comorbid conditions may lead
to drug-drug interactions or compliance issues [19]; in-
creasing age may result in a changing metabolic profile
that impacts some drugs [20]; the increasing cost of med-
ications may be overwhelming for some patients, causing
them to stop taking medications; and/or fixed-dose com-
binations may not provide the appropriate dose of one of
the component medications to meet an individual’s needs.
The potential challenges of using combination therapies
for the management of some hypertensive patients with
additional risk factors might indicate the need for future
innovative drugs specialized for such subpopulations.
Bearing this in mind, one must treat the individual, not
the individual symptoms.
Due to the period of study, the renin inhibitor drug
class was not considered in this study and, consequently,
no assessment can be made with regard to this drug
class. Furthermore, these study results are subject to the
quality and availability of the EMR data collected by the
participating physicians. Only one BP measurement clos-
est to the end of the follow-up period was used, which
may have created some challenges in determining BP
control. However, most patients would have been treated
for an extended period of time at the end of follow-up,
and BP control should have been established. An add-
itional limitation of this study was that a relatively im-
balanced proportion of patients were lost to follow-up in
the two populations (about 25 % in the French and 60 %
in the Italian), and it is difficult to tell if the data were
randomly or systematically lost. However, this is a reflec-
tion of the real-world environment in which the study
was conducted and indicates a greater need for adher-
ence to guidelines, better quality of control and record-
ing of patient data regardless of outcome, and greaterfollow-up with patients. Given the limitations of the clin-
ical settings where these data were collected, generalization
of these findings to the wider population should be made
with caution.
Conclusion
This study confirms that the majority of treated hyper-
tensive patients in France and Italy have at least one
associated additional CVD risk factor. Despite many
treatment options available, attainment of blood pres-
sure targets was substantially less optimal in patients
with at least one associated CVD risk factor compared
with patients without any associated CVD risk factors.
The findings from this study can be used by health care
providers to help identify gaps in quality of care for
patients being treated for hypertension and to review
appropriate interventions and follow-up patterns.
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